Danvilostomig clinical trials
How each study uses danvilostomig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the danvilostomig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- SI-B003
- 10
Studies by the year they started
10 studies that test it; most in 2023 (8)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 8 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Izalontamab brengitecan (7) · Izalontamab (2) · Immune checkpoint inhibitors (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9
Studies that test danvilostomig.
- Dec 2026A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerPhase 1/2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal TumorsPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
- Dec 2026A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological MalignanciesPhase 2 · Sichuan Baili Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses danvilostomig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05924841Written as SI-B003
- A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06042894Written as SI-B003
- A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06006169Written as SI-B003
- A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05956587Written as SI-B003
- A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05965856Written as SI-B003
- A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal TumorsRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06008054Written as SI-B003
- A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological MalignanciesRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT05990803Written as SI-B003
- A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05668858Written as SI-B003
- A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingPhase 1/2Sichuan Baili Pharmaceutical Co., Ltd.NCT05949606Written as SI-B003
- A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsActive, not recruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT04606472Written as SI-B003
Given beside what is tested · 1 — danvilostomig is usual care or a partner of the new treatment
Codes
What other systems call danvilostomig · ClinicalTrials.gg INT016068
- UNII (FDA) B4Q67YX49QDANVILOSTOMIGOne source FDA
- NCI Thesaurus C178449DanvilostomigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B4Q67YX49Q | DANVILOSTOMIG | One source FDA |
| NCI Thesaurus | C178449 | Danvilostomig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.